Infectious Disease

// R&D pipeline

eTheRNA has formed a consortium with North American and European partners to access tools to develop a novel mRNA vaccine against CoV-19.

Administered intranasally, the proposed vaccine is intended primarily for high risk populations such as healthcare workers and families of confirmed cases.
It is also designed to be protective against future variations of the virus by targeting conserved epitopes from the whole CoV-19 genome.

eTheRNA and its partners have extensive experience in the mRNA vaccine field and this will help accelerate progress towards clinical trials with patient enrolment planned for early 2021.